Antibodies

9 July 2010

Adimab Announces Fifth Major Pharmaceutical Partnership in First Year After Launch of Novel Antibody Discovery Platform

8 July 2010

Western States Biopharmaceuticals and University of Colorado Announce Exclusive Licensing Agreement for TCISM Targets to Treat Autoimmune Diseases

7 July 2010

Genentech Submits Application to FDA for Trastuzumab-DM1 in Previously Treated Advanced HER2-Positive Breast Cancer

7 July 2010

Genmab Announces Interim Results of Ofatumumab Phase II Study in Multiple Sclerosis

7 July 2010

European Commission Approves ORENCIA in Combination with Methotrexate for Earlier Use as First-Line Biologic after DMARD Inadequate Response for the Treatment of Rheumatoid Arthritis

6 July 2010

Cornerstone Therapeutics Reacquires HMGB1 Protein Technology Platform

2 July 2010

Second Phase III Study Showed Avastin-Containing Regimen Helped Women With Ovarian Cancer Live Longer Without Their Disease Getting Worse

1 July 2010

GlaxoSmithKline and Genmab announce amendment to Ofatumumab agreement

30 June 2010

XOMA Achieves Planned Enrollment Goal for Phase 2b Clinical Trial of XOMA 052 in Type 2 Diabetes

28 June 2010

Eisai and Morphotek, Inc. Announce Initiation of MORAb-022 Study in Europe for the Treatment of Inflammatory Disease

28 June 2010

FDA Resets its Decision Date For Motavizumab

28 June 2010

Theraclone Sciences Technology Uncovers Rare Anti-Influenza Antibodies

27 June 2010

MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program

26 June 2010

Preclinical Results With XOMA 052 in Type 2 Diabetes Presented at American Diabetes Association 70th Scientific Sessions

25 June 2010

Epratuzumab Data From Phase IIB EMBLEM(TM) Study Presented at 9th International Congress on Systemic Lupus Erythematosis

25 June 2010

Anti-GITR Combined with Chemotherapy Achieved Tumor Reduction and Survival Benefit in Animal Model

25 June 2010

ImmunoGen, Inc. Earns Milestone with Start of SAR650984 Clinical Trial

25 June 2010

Human Genome Sciences Announces Presentation of Additional Phase 3 SLE Study Results for BENLYSTA (Belimumab) at International Congress on SLE

25 June 2010

Basilea provides update on phase III program for the antifungal isavuconazole

24 June 2010

Pfizer Suspends Tanezumab Osteoarthritis Clinical Trial Program

23 June 2010

FDA Approves Lucentis (Ranibizumab Injection) for the Treatment of Macular Edema Following Retinal Vein Occlusion

21 June 2010

Pfizer Prepares For Voluntary Withdrawal Of U.S. New Drug Application And For Discontinuation Of Commercial vailability Of Mylotarg

18 June 2010

New Phase II study in gout patients shows Novartis ACZ885 prevented acute flares better than standard anti-inflammatory therapy

17 June 2010

HUMAN GENOME SCIENCES AND GLAXOSMITHKLINE ANNOUNCE FULL PRESENTATION AT EULAR OF BLISS-76 PHASE 3 STUDY RESULTS FOR BENLYSTA® IN SYSTEMIC LUPUS ERYTHEMATOSUS

17 June 2010

Positive Clinical Findings Presented on XOMA 052 in Debilitating Eye Disease

16 June 2010

Long-term Cimzia® (certolizumab pegol) Data Demonstrated Rapid Sustained Improvements in Clinical Outcomes and Quality of Life in Moderate to Severe Rheumatoid Arthritis (RA) Patients

16 June 2010

New Data for Investigational Antibody Blocking IL-6 in Rheumatoid Arthritis Patients to be Presented at Annual Congress of European League Against Rheumatism

16 June 2010

New Data From EMBLEM(TM) Study Show Pipeline Drug Epratuzumab Provided Significant Efficacy for Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus

15 June 2010

Immunomedics Doses First Patient in Phase I/II Study of Milatuzumab-Doxorubicin Conjugate for Multiple Myeloma Therapy

15 June 2010

Micromet’s Blinatumomab Induces Durable Remissions in Patients with Relapsed Non-Hodgkin’s Lymphoma

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

TL1A Inhibitor Pipeline Review

Bispecific Antibodies for Immuno-Oncology & Other Diseases

PD-1 Agonists Pipeline Review

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

CD40 Agonists & CD40/L Antagonists Pipeline Review

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Nectin-4-Targeted Immunotherapy Pipeline Review

EpCAM-Targeted Antibodies Pipeline Review